Department of Urology, University Hospitals, Leuven, Belgium.
San Raffaele Scientific Institute, Urological Research Institute, Department of Urology, Milan, Italy.
Eur Urol. 2015 Jan;67(1):157-164. doi: 10.1016/j.eururo.2014.01.020. Epub 2014 Jan 25.
High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory.
To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors.
DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers.
Retropubic radical prostatectomy with pelvic lymphadenectomy.
Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage (< cT3 vs cT3-4), Gleason score (GS) (2-7 vs 8-10), and prostate-specific antigen (PSA; ≤ 20 ng/ml vs > 20 ng/ml). The first "extended" model includes all seven possible combinations; the second "simplified" model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA >20 ng/ml and stage cT3-4); and a poor prognosis subgroup (GS 8-10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups.
The simplified model yielded an R(2) of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R(2): 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively (p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period.
This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting.
高危前列腺癌(PCa)是一种极具异质性的疾病。明确预后亚组的定义是必要的。
基于不利危险因素的组合,为高危 PCa 的 PCa 特异性生存(PCSS)建立一种预处理预后模型。
设计、设置和参与者:我们进行了一项回顾性多中心队列研究,纳入了在 8 个欧洲大容量中心接受治疗的 1360 例连续高危 PCa 患者。
经耻骨后根治性前列腺切除术联合盆腔淋巴结清扫术。
构建了两个 Cox 多变量回归模型,以预测 PCSS 作为临床分期(< cT3 与 cT3-4)、Gleason 评分(2-7 与 8-10)和前列腺特异性抗原(PSA;≤ 20ng/ml 与> 20ng/ml)二分法的函数。第一个“扩展”模型包括所有 7 种可能的组合;第二个“简化”模型包括 3 个亚组:预后良好亚组(单个高危因素);预后中等亚组(PSA>20ng/ml 且分期为 cT3-4);预后不良亚组(GS 8-10 与至少一个其他高危因素相结合)。总结了模型的预测准确性并进行了比较。比较了三个亚组之间的生存估计和临床病理结局。
简化模型的 R²为 33%,5 年 AUC 为 0.70,与扩展模型相比,预测准确性没有显著下降(R²:34%;AUC:0.71)。5 年和 10 年的 PCSS 率分别为良好、中等和差预后亚组的 98.7%和 95.4%、96.5%和 88.3%、88.8%和 79.7%(p=0.0003)。总体生存、临床无进展生存率和组织病理学结局从良好预后亚组到不良预后亚组呈逐步恶化。研究的局限性是回顾性设计和较长的研究期。
本研究提出了一种直观且易于使用的高危 PCa 分层方法,将其分为三个预后亚组。该模型可用于治疗前咨询和决策制定。